Skip to content

Intestinal Flora and Major Depressive Disorders

Investigation Into the Diversity and Dynamic Succession of Gut Flora Pre- and Post-remission in Major Depressive Disorder

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04347577
Acronym
IFMDD
Enrollment
40
Registered
2020-04-15
Start date
2020-04-10
Completion date
2023-04-01
Last updated
2020-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

major depressive disorder, Intestinal flora, remission

Brief summary

As an important micro-ecological factor in human body, intestinal flora is closely related to the occurrence and development of major depressive disorder. The purpose of our study is to investigate a microbiome probe of depression. This study is a 6-months open trial that will enroll approximately 30 patients in major depressive disorders and 10 age- and sex-matched healthy controls. We will comparing gut bacteria community structures of pre- treatment, those of 1 month and 6 months after treatment to remission. With the microbiome change in a preliminary analysis of pre-and post-treatment, we will reveal the diversity before and after the depression treatment.

Detailed description

Participants (30 patients and 10 controls) will be recruited in the clinical psychological department of Beijing Chaoyang hospital. Patients with first-episode major depressive disorder confirmed by structured diagnostic interview (Chinese mini version) and assessment of symptom severity (Hamilton Depression Scale-17, HAMD-17) will be enrolled in a six-month open study. Healthy controls matched for age, sex and body-mass index (BMI) will have only baseline stool and electroencephalography (EEG) collections. We then will make an assessment of HAMD-17, patient-reported outcomes, and EEGs identified at the pre-treatment and those same parameters at the 1- to 6-month point. Treatment response (50% reduction in HAMD-17), treatment remission (HAMD-17\<7, at least 3 weeks) will be analyzed with change in microbiome, inflammation markers and EEG. We will analyze the differences in the intestinal flora community structure and diversity of patients and controls in order to obtain information on key different bacteria. We will conduct the correlation between each genus of bacteria in the intestinal flora and the total score of HAMD-17 in order to reveal the dynamic succession change of the intestinal flora with the disease state of major depressive disorder. The analysis with multiple testing corrections will be analyzed between depressive severity, EEG and gut microbiome composition. The results of this study will provide the objective and direct biomarkers for major depressive disorder to achieve remission. This study will bring an important scientific basis to further optimizing treatment methods and improvie clinical effect.

Interventions

DRUGduloxetine

open-label study

Sponsors

Capital Medical University
CollaboratorOTHER
Beijing Chao Yang Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* The proportion between male and female in each of groups was 1:1 * Han Chinese * Permanent resident population of Beijing * Body Mass Index,18.5-23.9 * Signed informed consent

Exclusion criteria

* Other severe mental disease diagnosis * Alcohol and other substance abuse or dependence * Patients with contraindicated signs of duloxetine * A history of clinically significant physical disorders, including any cardiovascular, liver, kidney, respiratory, blood, endocrine, and neurological disorders, as well as clinically significant laboratory abnormalities of unstable or expected therapeutic intervention during the study period * The apparent risk of suicide and/or the patient is considered by the investigator to be at serious risk of suicide * Patients who had received antibiotics, probiotics and hormones within one month

Design outcomes

Primary

MeasureTime frameDescription
the difference between the florapre-treatmentThe potential differences in the microbiome between depressed patients and healthy controls

Secondary

MeasureTime frameDescription
the dynamic succession change of the intestinal flora0-1-6 monthscorrelation between each genus of bacteria in the intestinal flora and the total score of HAMD-17

Countries

China

Contacts

Primary ContactHui Shi, Doctor
dlshihui@163.com086-13810427166

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026